Skip to main content
. 2017 Apr 3;6(4):e310. doi: 10.1038/oncsis.2017.14

Figure 4.

Figure 4

Overview of Wnt signaling regulators contributing to TNBC progression and their targeted therapies. Canonical and non-canonical Wnt pathways are activated through Fzd, LRP and ROR receptors. Blue arrows indicate suppression/inhibition of Wnt regulators and pathways (with a net result of downregulation of Wnt target gene transcription, indicated by yellow cross); red arrows indicate activation of Wnt regulators and pathways.